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Summary Objective: To describe the variability of the asthma phenotype in patients
with mild persistent asthma enrolled in the Mild Asthma Montelukast versus Inhaled
Corticosteroid (MIAMI) study.
Methods: The variability of asthma rescue-free days, asthma symptoms, albuterol
use, medical resource use, and exercise limitations among patients with
documented mild persistent asthma was compared between the month before
study enrollment and the last 2 weeks of the run-in period.
Results: Patients eligible for randomization (n ¼ 400), aged 15–85 years, exhibited
symptoms (mean7SD) 3.671.3 days/week, b-agonist use 3.571.3 days/week, and
normal FEV1 (94.079.9% predicted) during the last 2 weeks of the run-in period. In
the year before enrollment, medical intervention for asthma flares was common:
38.5% made office visits, 15.8% had oral corticosteroids, and 8.3% required
emergency room or hospitalized care. In the month before enrollment, 11.8%
experienced daily symptoms, and 28.3% had limitations of normal activity. Patients
with daily symptoms in the month before study enrollment, compared with those
having less-than-daily symptoms, experienced fewer rescue-free days (P ¼ 0:024)
and had more days per week with symptoms (P ¼ 0:008) and requiring albuterol
(P ¼ 0:048) during the run-in; FEV1 was similar for both groups (93.1% vs. 94.2%
predicted, respectively).
Conclusion: Patients with mild persistent asthma reported a substantial disease
burden in the year before enrollment. The asthma burden experienced by these
patients both before and during the run-in period was of sufficient severity to
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support the recommendation that mild persistent asthma should be managed with
daily controller therapy.
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Introduction
Asthma afflicts approximately 7% of the total US
population (B17 million individuals), including 7–
8% of US children (B5 million children).1–4 It is
estimated that approximately 20–30% of these
patients have mild persistent asthma,1,5,6 defined
as either 3–6 days of symptoms per week or
increased peak expiratory flow variability in the
presence of normal predicted FEV1. Patients
with mild persistent asthma have significant
airway inflammation1,7,8 that potentially may
lead to lung remodeling,7 as recently documented
by computerized lung tomography.9 Although asth-
ma may appear mild, acute exacerbations may be
life threatening: up to 33% of asthma-related
deaths in a pediatric population occurred in
individuals thought to have only trivial or mild
asthma.10
The 2002 updates from the Global Initiative on
Asthma (GINA11) and the National Asthma Educa-
tion and Prevention Program (NAEPP1) recommend
low-dose inhaled corticosteroid therapy as the
preferred first-line treatment for mild persistent
asthma in both children and adults. However, this
recommendation is based on trials that included
patients with both mild and moderate persistent
asthma. Until recently there have been few studies
of patients with exclusively mild persistent asth-
ma.7,12–24 These expert panels recognized the
scarcity of head-to-head comparisons between
asthma controllers in mild persistent asthma and
recommended long-term trials to compare their
effectiveness in this subgroup. To address this
need, a randomized, parallel-group study, the Mild
Asthma Montelukast versus Inhaled Corticosteroid
(MIAMI) study, was designed to compare the effects
of the leukotriene receptor antagonist, montelu-
kast, and the inhaled corticosteroid, fluticasone,
in patients with mild persistent asthma during a
12-week double-blind treatment period followed
by a 36-week open-label period. This study affords
the opportunity to assess the asthma burden of a
cohort of adolescents and adults with mild persis-
tent asthma during the year before the study and
during a 3-week run-in period. This report docu-
ments that patients with mild persistent asthma
eligible for participation in the MIAMI study
experienced a substantial asthma burden and
possessed a variable asthma phenotype.
Methods
Overview of MIAMI
MIAMI is a randomized two-arm, parallel-group,
multicenter study of adults and adolescents with
mild persistent asthma designed to determine
whether oral montelukast (10mg once daily) will
provide a comparable percentage of asthma res-
cue-free days (RFD) as inhaled fluticasone (88 mg
twice daily) during 12 weeks of double-blind
therapy (primary outcome) and a subsequent
36-week open-label treatment period. A RFD is
defined as a treatment day during which there is no
asthma rescue medication use (i.e., inhaled albuterol
or oral corticosteroids) and no rescue clinical care
(i.e., unscheduled asthma care in the office, urgent
care center, emergency department, or hospital).
Recruitment and eligibility
Institutional review boards at each study site
approved the study protocol, and written informed
consent was obtained from all patients and from
the parents or guardians of patients under 18 years
of age before enrollment. Male and female out-
patients between the ages of 15 and 85 years with a
history of intermittent or persistent asthma symp-
toms for at least 4 months before enrollment and
na.ıve to systemic corticosteroids for at least 4
weeks, inhaled corticosteroids, cromolyn, nedocro-
mil, or leukotriene modifiers for at least 2 weeks,
and theophylline, long-acting beta-agonists, or
inhaled anticholinergic agents for at least 1 week
before enrollment were screened to identify a
cohort with mild persistent asthma. Patients meet-
ing the NAEPP1 and GINA11 definitions of mild
persistent asthma based on symptoms, albuterol
use, and lung function during screening and run-in
were eligible for the study.
Eligible patients had an average FEV1 during the
run-in period X80% of predicted, with none of the
qualifying values below 70%, and daytime symp-
toms and short-acting b-agonist use on an average
of X2 days but p6 days per week during the last 2
weeks of run-in period before randomization.
Patients were also required to demonstrate airway
reversibility or reactivity by showing at least a 12%
absolute increase in FEV1
25 or PEF after albuterol, a
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methacholine PC20 FEV1p12.5mg/ml,26,27 or a
decrease in FEV1 of at least 15% during an exercise
challenge.11,28
Atopy was determined by serum assay using the
qualitative CAP Phadiatop test (Pharmacia Diagnos-
tics, Kalamazoo, Michigan), which determines the
presence of allergen-specific IgE antibodies to any
component of a mixture of common inhalant
allergens (house dust mite; cat; dog; horse;
cockroach; various grass, weed, and tree pollens;
and mold spores). The Phadiatop assay gives a
‘‘Yes’’ or ‘‘No’’ result for the presence of atopy. The
sensitivity and specificity of the Phadiatop assay
are 96% and 94%, respectively.
Patients were excluded from the study if they
had (1) an acute or chronic pulmonary disease in
addition to asthma; (2) a hospitalization for asthma
within the previous 3 months; (3) an emergency
department/urgent care facility or office setting
treatment for acute asthma within the month
before Visit 1; or (4) used intravenous gamma
globulin or immunosuppressants within 1 month or
fexofenadine, loratadine, or cetirizine within 2
days of enrollment.
Study visits
A run-in period of 3 weeks was used to assess
asthma severity and ensure a mild persistent
asthma cohort. To minimize placebo effect during
the randomized interventional period, all potential
patients received single-blind placebo montelukast
and fluticasone during the last 2 weeks of the
3-week run-in period (Period 1 of study). Also during
this period, FEV1, PEF, daytime symptoms, and
b-agonist use were assessed to determine eligibility
for randomization and to establish baseline values.
Before all scheduled clinic visits, inhaled
b-agonists were withheld for at least 6 h, and
antihistamines were withheld for at least 48 h.
Spirometry was performed at least twice during the
run-in period, in accordance with and using
spirometers conforming to the American Thoracic
Society (ATS) guidelines.25
Study questionnaires
Patients completed an asthma and allergy history
questionnaire and an Exercise Questionnaire29,30 at
enrollment and the Exercise Questionnaire and the
Asthma-Specific Quality-of-Life Questionnaire31,32
prior to randomization. To determine asthma
severity according to both GINA11 and NAEPP1
guidelines, patients were queried on the frequency
of asthma symptoms and night awakenings during
the previous month. The following two questions (5
possible responses each) were asked: (a) In the past
month, on average, how often did you have
symptoms of asthma: never, r2 times per week,
42 times per week but not every day, every day, or
continuously and (b) In the past month, on average,
how often did you awaken during the night or early
morning because of asthma symptoms: never, r2
times per week, 42 times per week but not every
day, every day, or continuously. In addition,
patients answered other questions concerning
asthma symptoms, assessment of therapy, work
and productivity loss, and asthma activity via a
telephone interview just prior to randomization.
Data analysis
Analyses were performed using baseline data
obtained during screening and during the run-in
period for all randomized patients. Descriptive
analyses [percentages, means, and associated 95%
confidence intervals (CI)] were used to characterize
the demographics and asthma phenotype of the
cohort.
To understand the variability in asthma severity
in a cohort with documented mild persistent
asthma, the cohort was stratified by the degree of
asthma symptoms experienced in the month before
enrollment. Two groups were defined: a group who
reported at least daily symptoms (more consistent
with moderate persistent asthma), and a group
with less frequent symptoms in the month before
enrollment. Those who reported daily symptoms in
the month before randomization did not have daily
symptoms during the last 2 weeks of the run-in
period and so were not excluded from the study.
These groups were compared with respect to
asthma resource use in the prior year and asthma
control during the last 2 weeks of the 3-week
placebo run-in period. An exploratory analytical
comparison across these subgroups was performed.
For continuous data, the group means were
compared using the t-distribution and associated
95% CIs on the group difference. For discrete data,
the group percentages were compared using
exact 95% CIs on the difference of two binomial
proportions.
Results
Cohort baseline characteristics
Nine hundred patients attended a screening visit
for participation in MIAMI, 735 patients entered the
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placebo run-in period, and 400 were randomized
into the study. Of those patients who were not
randomized, most (401 patients) were excluded
for not meeting eligibility criteria; the most
common reasons were FEV1 too low, spirometry
technique unacceptable, and b-agonist reversibility
o12%.
The 400 randomized patients in the MIAMI study
had been first treated for asthma at a mean age of
20.6716.1 years and were predominately female,
white, and atopic (Table 1). The cohort met the
NAEPP and GINA guidelines for mild persistent
asthma during the last 2-weeks of the run-in
period: daytime asthma symptoms per week (mean
3.671.3 days), albuterol use per week (mean
3.571.3 days), FEV1 (mean 94.079.9%), and
number of nighttime awakenings (42 per month
but not 41 time per week: 34.8%; p2 per month:
65.3%; Table 1). Patients had evidence of airway
reversibility or reactivity based either on a X12%
increase in FEV1 or PEF (55.5% and 77.3% of
patients, respectively), methacholine PC20
FEV1p12.5mg/ml (1.3% of patients), or X15%
decrease in FEV1 after exercise (1.3% of patients).
Asthma burden in mild persistent asthma
Mild persistent asthma was associated with a
substantial asthma burden both in the month and
in the year before the study. In the previous year,
38.5% had at least one physician office visit for
asthma worsening, 15.8% required a course of
oral corticosteroid for an asthma flare-up, and
8.3% of patients reported an emergency depart-
ment visit or hospitalization (Fig. 1). In addition, in
the month before enrollment, 11.8% experienced
daily symptoms (Fig. 2), and 28.3% reported moder-
ate-to-severe limitations to normal activity (Fig. 3).
Based on the history of asthma symptoms from
the month before the study, the cohort was
stratified into those with at least daily symptoms
and those with less-than-daily symptoms (n ¼ 47
and n ¼ 353; respectively). These two groups were
similar with respect to demographic characteris-
tics, atopic status, and FEV1 (Table 2). During the
run-in period, as previously described, all patients
reported b-agonist use as less than daily on a
questionnaire and had an FEV1 greater than 80%
predicted. However, during the last 2 weeks of the
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Table 1 Patient baseline characteristics.
Randomized patients N ¼ 400
Mean age, years (SD) 35.0 (14.2)
Males/females (%) 30.5/69.5
Ethnicity (% Caucasian) 81.0
Atopy, % positive Phadiatop 79.8 (n ¼ 377)
Mean age first treated for asthma, years (SD) 20.6 (16.1)
FEV1
Mean liters (SD) 3.26 (0.7)
Mean % predicted (SD) 94.0 (9.9)
Nighttime awakenings (p2 per month,42 per month) during the run-in period (%) 65.3/34.8
Mean b-agonist use, days/week (SD) during last 2-weeks of the run-in period 3.5 (1.3)
Mean daytime asthma symptoms, days/week (SD) during last 2-weeks of the run-in
period
3.6 (1.3)
Mean RFDs as % of days in run-in period (SD) during last 2-weeks of the run-in period 57.6 (31.3) (n ¼ 344)n
RFD: rescue-free day (no short-acting b-agonist or oral corticosteroids).
nFaulty electronic devices in 56 patients.
Figure 1 Patient-reported asthma medical resource and
oral corticosteroid use in the past year. Bars represent
the percentage of patients (N ¼ 400) reporting visits to a
physician’s office (in-office), the emergency department
(ED), or hospitalizations because of asthma symptoms
during the past year. The percentage of patients who
received a course of oral steroids for asthma symptoms
during the past year is also shown.
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3-week placebo run-in period, patients with a
recent history of daily asthma symptoms experi-
enced fewer asthma RFDs (Fig. 4; P ¼ 0:024), more
days per week with symptoms (Fig. 4; P ¼ 0:008),
and more b-agonist use (Fig. 4; P ¼ 0:048) com-
pared with patients with less-than-daily symptoms.
Additionally, in the year before the study, although
not significant, there was almost a doubling of need
for asthma emergency care or hospitalizations in
the cohort with recent daily symptoms (Table 2).
Discussion
The present analysis of baseline characteristics of
the MIAMI cohort documented variability in degree
of asthma severity during the 2-week placebo run-in
period, even among patients with mild persistent
asthma. Despite mean FEV1 levels of 94% predicted,
this cohort had a history in the past year of substantial
medical resource utilization due to asthma, require-
ment for oral course of corticosteroids, and limitation
of normal activity (Tables 1 and 2). In addition, 11.8%
of the cohort experienced asthma symptoms daily in
the month before enrollment. This subgroup with
recent daily symptoms experienced significantly fewer
RFDs, more days with asthma symptoms, and greater
use of rescue bronchodilator during the run-in period
than those with less frequent symptoms. Moreover, the
medical resource use for asthma of those with daily
symptoms was greater in the year before enrollment,
although this difference did not reach statistical
significance (Table 2).
The presence of significant variability in disease
expression in mild asthma is not surprising. Pauwels
and colleagues noted a substantial disease burden,
including life-threatening asthma exacerbations
and need for systemic corticosteroid courses, in a
large cohort of children and adults with recent-
onset mild persistent asthma.24 Zhang and collea-
gues33 highlighted the short-term disease variabil-
ity in FEV1 and symptom measurements in a
population of mild-to-moderate asthmatics and
cautioned that awareness of this variability is
necessary in assessing the impact of therapy. While
the presence of such variability in disease expres-
sion may confound both the classification of asthma
severity and the measured response to therapy, it
nonetheless highlights the importance of daily
treatment to reduce morbidity.
Few studies have been conducted exclusively in
patients with mild persistent asthma. Based on
expert opinion, the GINA11 and NAEPP1 guidelines
recommend continuous daily use of controller
therapy for mild persistent asthma, including ICS
(preferred choice), cromolyn, nedocromil, and
leukotriene modifiers to minimize the conse-
quences of asthma in these patients. Despite a
decade of dissemination of these guidelines, many
physicians still do not follow these recommenda-
tions sufficiently and are still undertreating pa-
tients with persistent asthma with controller
therapy.34,35 The evidence of substantial disease
burden in mild persistent asthmatics presented in
this study further supports the GINA and NAEPP
guidelines and should foster physician awareness of
the variability and impact of asthma in this cohort.
Hopefully, this awareness will encourage them to
treat this asthma subgroup more aggressively and
appropriately with chronic controller medication.
Specific therapy choices for patients with mild
asthma must be individualized and, ideally, should
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Figure 2 Patient-reported recent asthma symptoms in
the month before enrollment. Bars represent the
percentage of patients (N ¼ 400) reporting the indicated
frequency of symptoms during the month before enroll-
ment.
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Figure 3 Limitation of normal activity. Bars represent
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limitation of the indicated severity on their normal
activities because of asthma symptoms in the month
before the study.
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be influenced by comparative data from trials
conducted exclusively in patients with mild dis-
ease. Particularly because these patients are
frequently asymptomatic and may not perceive a
benefit of therapy, it is important to determine the
efficacy and safety under well-controlled experi-
mental conditions, as well as the patient’s percep-
tion of benefits from the drug and long-term
adherence with treatment in a naturalistic setting,
as in the design of the MIAMI study.
Studies of patients with mild persistent asthma
present unique challenges. Recruitment of a mild
cohort is difficult because patients who do not feel
ill are reluctant to participate in a trial of daily
controller medication. In the present study, more
than two patients were screened for each patient
finally fulfilling the requirement for randomization.
Assessment of efficacy cannot be limited to indices
of airway caliber, which are typically used to assess
more severe forms of asthma, because they are
already normal or near normal at baseline in
ARTICLE IN PRESS
Table 2 Baseline profile in subgroups related to symptom frequency in the month before enrollment.
Parameter Daily symptoms pre-
study, N ¼ 47
Less-than-daily
symptoms pre-study,
N ¼ 353
Difference (daily–less-
than-daily) (95% C.I.)
Mean Age, years (SD) 33.2 (13.2) 35.2 (14.3) 2.0 (6.3, 2.4)
Females (%) 74.5 68.8 5.6 (9.6, 21.2)
Caucasian (%) 83.0 80.7 2.2 (12.4, 17.8)
Atopic dermatitis (%) 31.9 (n ¼ 47) 21.9 (n ¼ 352) 10.0 (3.8, 27.4)
Atopy, % positive Phadiatop 80.0 (n ¼ 45) 79.8 (n ¼ 332) 0.2 (15.2, 16.2)
History in past year
Emergency or hospital care (%) 14.9 7.4 7.5 (2.7, 23.7)
Office visits (%) 42.6 38.0 4.6 (10.5, 22.0)
Oral corticosteroid courses (%) 17.0 15.6 1.4 (9.9, 18.2)
Run-in period
FEV1
Liters, mean (SD) 3.24 (0.6) 3.26 (0.8) 0.02 (0.25, 0.21)
% predicted, mean (SD) 93.1 (9.2) 94.2 (10.0) 1.1 (4.1, 2.0)
Daytime symptoms, days/week,
mean (SD)
4.1 (1.5 ) 3.5 (1.3) 0.5 (0.1, 0.9)
RFDs as % of days, mean (SD) 46.8 (30.7) (n ¼ 38) 58.9 (31.2) (n ¼ 306) 12.1 (22.6, 1.6)
Nighttime awakenings (%)
42 per month 46.8 33.1 13.7 (1.6, 31.0)
p2 per month 23.4 26.3 2.9 (18.5, 12.2)
Never 29.8 40.5 10.7 (26.2, 4.6)
b-agonist use, days/week, mean (SD) 3.9 (1.5 ) 3.5 (1.3 ) 0.4 (0.0, 0.8)
Limitation of normal activity (%) 80.9 72.0 8.9 (6.1, 24.4)
Moderate-to-severe limitation of
exercise (%)
53.2 41.4 11.8 (3.6, 29.1)
RFD: rescue-free day.
Figure 4 Baseline characteristics in subgroups related to
recent symptom frequency. Bars represent the mean
number of days per week (þ standard error bars) during
the last 2 weeks of the run-in period for daytime asthma
symptoms (left), b-agonist rescue medication use (mid-
dle), or rescue-free days (right) based on daily symptoms
(n ¼ 47) versus less-than-daily symptoms (n ¼ 353) dur-
ing the month before enrollment. Black bars¼ daily
symptoms 1 month before run-in; striped bars¼ less-
than-daily symptoms 1 month before enrollment.
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patients with mild disease. The rescue-free day was
chosen as the primary endpoint in the MIAMI study
because of its established responsiveness to treat-
ment in a mild cohort36 and its reflection of the
goals of treatment.
The burden of asthma experienced by patients
with mild persistent asthma in the present analysis
supports the recommendation of GINA and NAEPP
to manage mild persistent asthma with daily
controller therapy to decrease the risk of poten-
tially life-threatening exacerbations and the need
for rescue medication.1,11 Because of the scarcity
of comparative studies in patients with mild
persistent asthma,18,21–23 physicians are forced to
choose between the various controllers recom-
mended by the guidelines based on trials conducted
in patients with more severe forms of asthma. To
better assess this selection process, the MIAMI
study has been designed to provide comparative
data for a leukotriene receptor antagonist and an
inhaled corticosteroid as monotherapy in patients
meeting the strict definition for mild persistent
asthma.
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